Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Herbst

Showing results (61-70 of 395) with videos related to

Pageof 40
Sort By:
Journal of Cellular Biochemistry|January 1, 1990
Cis effect of the type 5 adenovirus E1A gene enhancer element on cellular transformationR S Herbst, M Pelletier, L E Babiss
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2014
A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancerNeil Vasan, Julie L Boyer, Roy S Herbst
Cancer Chemotherapy and Pharmacology|April 29, 1998
Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma modelsR S Herbst, H Takeuchi, B A Teicher
Trends in Immunology|May 27, 2018
Defining and Understanding Adaptive Resistance in Cancer ImmunotherapyTae Kon Kim, Roy S Herbst, Lieping Chen
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2012
Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trialsDonald A Berry, Roy S Herbst, Eric H Rubin
Oncology (Williston Park, N.Y.)|September 2, 2004
Pemetrexed in advanced NSCLC: a review of the clinical dataRalph G Zinner, Frank V Fossella, Roy S Herbst
Expert Opinion on Therapeutic Targets|October 22, 2014
The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancerBrian S Henick, Roy S Herbst, Sarah B Goldberg
Nature Clinical Practice. Oncology|February 5, 2009
Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neckWilliam N William, Edward S Kim, Roy S Herbst
Current Opinion in Oncology|October 24, 2001
Epidermal growth factor receptor biology (IMC-C225)E S Kim, F R Khuri, R S Herbst
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2001
Emerging therapies in non-small-cell lung cancerF R Khuri, R S Herbst, F V Fossella
Pageof 40

Showing results (61-70 of 395) with videos related to

Sort By:
Pageof 40
Journal of Cellular Biochemistry|January 1, 1990
Cis effect of the type 5 adenovirus E1A gene enhancer element on cellular transformationR S Herbst, M Pelletier, L E Babiss
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 5, 2014
A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancerNeil Vasan, Julie L Boyer, Roy S Herbst
Cancer Chemotherapy and Pharmacology|April 29, 1998
Paclitaxel/carboplatin administration along with antiangiogenic therapy in non-small-cell lung and breast carcinoma modelsR S Herbst, H Takeuchi, B A Teicher
Trends in Immunology|May 27, 2018
Defining and Understanding Adaptive Resistance in Cancer ImmunotherapyTae Kon Kim, Roy S Herbst, Lieping Chen
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 3, 2012
Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trialsDonald A Berry, Roy S Herbst, Eric H Rubin
Oncology (Williston Park, N.Y.)|September 2, 2004
Pemetrexed in advanced NSCLC: a review of the clinical dataRalph G Zinner, Frank V Fossella, Roy S Herbst
Expert Opinion on Therapeutic Targets|October 22, 2014
The PD-1 pathway as a therapeutic target to overcome immune escape mechanisms in cancerBrian S Henick, Roy S Herbst, Sarah B Goldberg
Nature Clinical Practice. Oncology|February 5, 2009
Cetuximab therapy for patients with advanced squamous cell carcinomas of the head and neckWilliam N William, Edward S Kim, Roy S Herbst
Current Opinion in Oncology|October 24, 2001
Epidermal growth factor receptor biology (IMC-C225)E S Kim, F R Khuri, R S Herbst
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2001
Emerging therapies in non-small-cell lung cancerF R Khuri, R S Herbst, F V Fossella
Pageof 40